Welcome to the e-CCO Library!

P506: Steroid treatment for longer than 2 weeks leading to admission predicts higher colectomy rates in children with acute severe ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Tzivinikos*1, J. Jeng2, S. Nevitt2, C. Baillie1, S. Subramanian3, M. Auth1

Created: Friday, 22 February 2019, 9:41 AM
P506: The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Bertani, L.(1,2);Barberio, B.(3);Zanzi, F.(1);Maniero, D.(3);Ceccarelli, L.(4);Marsilio, I.(3);Minciotti, M.(2);Coppini, F.(1);Lorenzon, G.(3);Mumolo, M.G.(4);Zingone, F.(3);Costa, F.(4);Savarino, E.V.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Gadhok1, K. Fragkos2, S. Honap3, J. Hassan2, L. Whiteley2, A. Ibarra1, N. Burgess1, R. Vega2, E. Seward2, S. Mehta2, S. McCartney2, S. Bloom2, G. Parkes1, P. Irving3, J.O. Lindsay1, K.B. Kok1, F. Rahman2

Created: Thursday, 30 January 2020, 10:12 AM
P507: Clinical role, optimal timing and frequency of measurement of serum infliximab levels and anti-infliximab antibody titres in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Bor*1, K. Farkas1, A. Bálint1, A. Milassin1, M. Rutka1, M. Matuz2, F. Nagy1, A. Fábián1, Z. Szepes1, T. Molnar1

Created: Friday, 22 February 2019, 9:49 AM
P507: Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Viazis*1, E. Tsoukali1, M. Galanopoulos1, C. Pontas1, G. Karampekos1, G. Filippidis1, O. Giouleme2, G. Theocharis3, M. Tzouvala4, E. Archavlis1, A. Christidou1, G. J. Mantzaris1

Created: Friday, 22 February 2019, 9:41 AM
P507: Need for surgery in patients with ulcerative colitis in the era of biologic therapy.
Year: 2022
Source: ECCO'22
Authors: Zamora Olaya, J.M.(1);Aparicio-Serrano, A.(1);Gómez Pérez, A.(1);Ortiz Chimbo, D.S.(1);Rodríguez Tirado, M.I.(1);Soto Escribano, P.(1);Marín Pedrosa, S.(1);Iglesias Flores, E.(1);Benítez, J.M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P507: Nutrition status in pre-surgical Crohn's disease, active Crohn's disease, Crohn's disease in remission and ulcerative colitis in remission: a cross-sectional study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandall A.M.*1, Patel K.V.2, O'Hanlon D.V.3, Smith S.J.1, Darakhshan A.A.4, Sanderson J.D.2, Lomer M.C.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P507: United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Travis, S.(1)*;Bleakman, A.(2);Dubinsky, M.(3);Rubin, D.(4);Panaccione, R.(5);Hibi, T.(6);Kayhan, C.(2);Gibble, T.H.(2);Sapin, C.(2);Flynn, E.(2);Atkinson, C.(7);Schreiber, S.(8);
Created: Friday, 14 July 2023, 11:05 AM
P507: Vulvar Crohn’s disease: A challenging diagnosis
Year: 2021
Source: ECCO'21 Virtual
Authors: Sahar, N.(1);Dahmani, W.(1);Nour, E.(1);Aya, H.(1);Wafa, B.A.(1);Aida, B.S.(1);Ahlem, B.(1);Mehdi, K.(1);Hanene, J.(1);Ali, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P507: What is the impact of infliximab metaoptimisation on surgical rates and need-to-change-therapy in real-world practice for severe inflammatory bowel disease?
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Lefebvre1, R. Cormons1, J.-L. Faucheron2, M. Baudrant3, B. Bonaz1, N. Mathieu4*

Created: Thursday, 21 February 2019, 9:14 AM
P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Goessens1, J.F. Colombel2, A. Outtier3, M. Ferrante3, M. Truyens4, T. Lobaton4, F. Baert5, P. Bossuyt6, A. Cremer7, E. Macken8, B. Strubbe9, J.F. Rahier1

Created: Thursday, 30 January 2020, 10:12 AM
P508: Association between clinical outcome and post induction CT-P13 trough levels at week 14, in patients with inflammatory bowel disease. Preliminary results in an observational multicentric study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Elosua González A.*1, Oyόn Lara D.1, Nantes Castillejo Ó.1, Ogueta Fernández M.Ά.2, Gutiérrez Mendizábal P.3, Muñoz Villafranca M.C.3, Gόmez Irwin L.4, Muñagorri Santos A.I.5, Rodríguez Lago I.6, Rodríguez Gutiérrez C.1 IBD Study Group from the Basque-Navarre Society of Gastrointestinal Diseases

Created: Wednesday, 20 February 2019, 10:36 AM
P508: Does corticosteroid therapy affect prognosis in inflammatory bowel disease patients hospitalised with Clostridium difficile infection?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Bar Yoseph1,2, H. Daoud3, D. Ben Hur1, Y. Chowers1,2, M. Waterman*1,2

Created: Friday, 22 February 2019, 9:41 AM
P508: Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
Year: 2021
Source: ECCO'21 Virtual
Authors: Rowbotham, D.S.(1);Scherl, E.J.(2);Sands, B.E.(3);Panaccione, R.(4);Peyrin-Biroulet, L.(5);Zhang, H.(6);Miao, Y.(6);Leong, R.W.(7);Afif, W.(8);Arasaradnam, R.P.(9);Danese, S.(10);Marano, C.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P508: Pregnancy outcomes in patients with inflammatory bowel disease experiencing flare ups during foetal development
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Yokoyama*1, H. Tanaka2, T. Miyazaki1, T. Sato1, M. Kawai1, Y. Kita1, K. Kamikozuru1, M. Iimuro1, N. Hida1, S. Nakamura1

Created: Friday, 22 February 2019, 9:49 AM
P508: Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in Korea
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.Y. Chang*, S.-A. Jung, C.M. Moon, S.-E. Kim, H.-K. Jung, K.-N. Shim

Created: Thursday, 21 February 2019, 9:14 AM
P508: Sarcopenia is associated with increased rates of infectious post-operative complications in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Simpson, K.(1)*;Inniss, S.(2);Fragkos, K.C.(1);Wood, C.P.J.(1);Smith, A.(2);Rahman, F.Z.(1);
Created: Friday, 14 July 2023, 11:05 AM
P508: The impact of disease duration and early biologic treatment on transmural healing in Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Revés, J.(1);Freire, G.(2);Sousa, P.(2);Primitivo, A.(2);Nascimento, C.(1);Morão, B.(1);Abreu, N.(3);Palmela, C.(1);Glória, L.(1);Torres, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sun1, B. Fennimore2, D.B. Beaulieu3, R. Arsenescu4, A. Stein5, J. Chen6, T. Lin7, S. McKnight8, M. Rosario9, R.A. Lirio10

Created: Thursday, 30 January 2020, 10:12 AM
P509: Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Sorokina Alexdóttir , M.(1);Bourgonje , A.R.(2);Karsdal , M.A.(1);Bay-Jensen , A.C.(1);Pehrsson , M.(1);Loveikyte , R.(2);van Dullemen , H.M.(2);Visschedijk , M.C.(2); A. M. Festen , E.(2);K. Weersma , R.(2);Faber , K.N.(2);Dijkstra , G.(2);Joachim H. , M.(1);
Created: Friday, 11 February 2022, 3:56 PM